Aclarion, Inc. last reported quarterly results on Feb 21, 2024, for the quarter ended Dec 31, 2023. It usually reports 46–56 days after a quarter ends.
Release dates are when the company filed its earnings announcement with the SEC (Form 8-K, Item 2.02); select a date to open the filing. It usually reports 46–56 days after a quarter ends. Figures are USD in millions, except EPS. The colored percent is the change from the same quarter a year earlier. Until a quarter's 10-Q or 10-K figures reach the SEC's data, they come from the earnings press release, and are shown only when its year-ago numbers match the filed ones. A dash means the figure could not be confirmed yet.
| Released | Quarter | Revenue | Net income | Diluted EPS |
|---|---|---|---|---|
|
Feb 21, 2024
52 days after quarter end
|
—
ended Dec 31, 2023
|
—
|
—
|
—
|
|
Aug 25, 2023
56 days after quarter end
|
—
ended Jun 30, 2023
|
—
|
—
|
—
|
|
May 16, 2023
46 days after quarter end
|
—
ended Mar 31, 2023
|
—
|
—
|
—
|
Company profile
- Industry
- Services-Medical Laboratories (SIC 8071)
- Listed as
- ACON (Nasdaq), ACONW (Nasdaq)
- Fiscal year ends
- December 31
- Incorporated in
- DE
- Headquarters
- Broomfield, CO
- SEC filer status
- Non-accelerated filer, Smaller reporting company, Emerging growth company
- SEC CIK
- 1635077
- Former names
- Nocimed, Inc. (until Oct 26, 2021)
Other Services-Medical Laboratories companies
- Natera, Inc. NTRA
- Labcorp Holdings Inc. LH
- Quest Diagnostics Inc DGX
- Guardant Health, Inc. GH
- Caris Life Sciences, Inc. CAI
- GRAIL, Inc. GRAL
- RadNet, Inc. RDNT
- BillionToOne, Inc. BLLN
Source: SEC EDGAR filings. This is company-reported data, not investment advice.